Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Bristol-Myers Squibb Co — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.66, while Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while YieldMax AMD Option Income Strategy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | BMY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $65.89 |
52-Week Low | $29.80 | $42.60 |
Market Cap | — | $129.94B |
Enterprise Value | — | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.90, up 3.01% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, including $0.68 on August 5, 2026, but key valuation ratios like P/E and P/S are unavailable. Recent news highlights high yield potential but cautions on net asset value erosion amid AMD stock volatility.
Outlook hinges on AMD's performance; the ETF offers income via call spreads but faces NAV decline risks if AMD rallies sharply. Investors should weigh high distributions against potential capital depreciation, with sentiment mixed among analysts citing sustainability concerns.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
